Recently, a polymorphism in the interleukin-28B (IL28B) gene region, encoding interferon-lambda 3, was identified as a strong predictive factor for response to antiviral treatment in nontransplant patients with hepatitis C [26], [27], [28]. This evidence concerns the gene IFNL3 and hepatitis C virus infection.